Home › Research › Tau biomarkers
Prognostic significance of cerebrospinal fluid tau biomarkers in amyloid-negative A-T + N + neurodegeneration: A retrospective cohort study
Aksoy Gündoğdu A, Samancı B, Alaylıoğlu M, Şahin E, Ulukan Ç, Gürvit İH, Dursun E, Hanağası HA et al.. Journal of Alzheimer's disease : JAD, 2026-08-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BackgroundAmyloid-negative tau-related neurodegeneration represents a non-Alzheimer biomarker-defined profile; however, its clinical heterogeneity and prognostic relevance remain unclear within Alzheimer's disease-related frameworks.ObjectiveTo characterize the clinical spectrum and identify predictors of mortality in patients with this profile.MethodsIn this retrospective cohort study, 1280 patients evaluated at a tertiary neurology center were screened, and 130 with an amyloid-negative cerebrospinal fluid (CSF) pattern [amyloid-β (Aβ) 42 normal, phosphorylated tau (pTau), and total tau (tTau) elevated] were included. Survival was assessed using Kaplan-Meier analysis, and predictors of mortality were evaluated using Cox models.ResultsThe cohort (mean age 68.8 ± 10.1 years; 45.4% female) showed heterogeneous diagnoses, mainly mild cognitive impairment and frontotemporal dementia (each 30
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 1,280 participants. Among 130 patients with an amyloid-negative but tau-elevated cerebrospinal fluid pattern, this retrospective cohort found heterogeneous diagnoses and that survival differed across diagnostic groups, with higher cerebrospinal fluid total tau predicting mortality. Reported effect size: 45.4%; 88.9%; 45.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Aksoy Gündoğdu, A., Samancı, B., Alaylıoğlu, M., Şahin, E., Ç, U., İH, G., et al. (2026). Prognostic significance of cerebrospinal fluid tau biomarkers in amyloid-negative A-T + N + neurodegeneration: A retrospective cohort study. Journal of Alzheimer's disease : JAD. https://doi.org/10.1177/13872877261476236
Vancouver
Aksoy Gündoğdu A, Samancı B, Alaylıoğlu M, Şahin E, Ç U, İH G, et al. Prognostic significance of cerebrospinal fluid tau biomarkers in amyloid-negative A-T + N + neurodegeneration: A retrospective cohort study. Journal of Alzheimer's disease : JAD. 2026. doi:10.1177/13872877261476236. PMID: 42585284.
BibTeX
@article{aksoygundogdu2026-42585284,
author = {Aksoy Gündoğdu, A. and Samancı, B. and Alaylıoğlu, M. and Şahin, E. and Ç, Ulukan and İH, Gürvit and Dursun, E. and Hanağası, H. A. and others},
title = {{Prognostic significance of cerebrospinal fluid tau biomarkers in amyloid-negative A-T + N + neurodegeneration: A retrospective cohort study}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2026},
doi = {10.1177/13872877261476236},
pmid = {42585284},
url = {https://doi.org/10.1177/13872877261476236}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Survival was assessed using Kaplan-Meier analysis, and predictors of mortality were evaluated using Cox models.ResultsThe cohort (mean age 68.8 ± 10.1 years; 45.4% female) showed heterogeneous diagnoses, mainly mild cognitive impairment and frontotemporal dementia (each 30%).
- Survival differed across diagnostic groups (log-rank p = 0.037), with more favorable outcomes in mild cognitive impairment.
- Male sex was more frequent among non-survivors (88.9% versus 45.6%, p < 0.001).
- Higher CSF tTau levels were associated with mortality in the joint Cox model (HR 1.003, 95% CI 1.001-1.006, p = 0.006) and faster clinical progression (r = 0.22, p = 0.011).
Why it matters
Among 130 patients with an amyloid-negative but tau-elevated cerebrospinal fluid pattern, this retrospective cohort found heterogeneous diagnoses and that survival differed across diagnostic groups, with higher cerebrospinal fluid total tau predicting mortality. It describes prognosis in a non-Alzheimer biomarker profile and does not offer treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants1,280
- Effect size45.4%; 88.9%; 45.6%
- Evidence strengthModerate
How this study scored 47/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,280 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Başar Bılgıç: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Istanbul University: institution h-index 441 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42585284) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.